公开(公告)号：US20230295122A1

公开(公告)日：2023-09-21

申请号：US18041719

申请日：2021-08-18

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： David S. Yoon ,  Alicia Regueiro-Ren ,  Michael Mandler ,  Shoshana L. Posy ,  Chunjian Liu

IPC: C07D401/14 ,  C07D451/04 ,  C07D471/04 ,  C07D405/14 ,  C07D417/14 ,  C07D413/14 ,  C07D235/18 ,  C07D519/00 ,  C07D405/12 ,  C07D401/10 ,  C07D487/10 ,  C07D487/04 ,  C07D403/10 ,  C07D401/12 ,  C07D451/02

CPC classification number: C07D401/14 ,  C07D451/04 ,  C07D471/04 ,  C07D405/14 ,  C07D417/14 ,  C07D413/14 ,  C07D235/18 ,  C07D519/00 ,  C07D405/12 ,  C07D401/10 ,  C07D487/10 ,  C07D487/04 ,  C07D403/10 ,  C07D401/12 ,  C07D451/02

Abstract: The present invention relates to 1H-benzo[d]imidazole derivatives of formula (I) or a salt thereof. The present compounds are inhibitors of TLR9 and useful in treating preventing, or slowing fibrotic diseases, such as e.g. liver fibrosis, renal fibrosis, biliary fibrosis or pancreatic fibrosis, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC), or idiopathic pulmonary fibrosis (IPF).